>> Not a lawyer, but I believe the statement copied below from SEC document (section II under Timeliness) gave NP all the flexibility he needed to say absolutely nothing, if he chose. But he did opt to release the limited "neutral" PR this morning (which I view very positively for us shareholders, since there were hints of progress toward approval discussions) <<

>> (b) the information concerns an incomplete proposal or negotiations or the disclosure of particular information is such as to prejudice the legitimate interests of the entity’s investors; in such cases the listed entity must ensure that the information is maintained strictly confidential. <<

I had the same feeling that it was a positive pr and that CytoDyn might be in discussions with a bigger player - really, can a 20 employee company handle billions of dollars in sales with the partners they now have? But yet the stock tanked. If they had announced whether or not the trial met the primary endpoint and how many deaths had occurred in each arm and what the p-value was, the market reaction would most likely have been the opposite of what it was. Aside from the above considerations, why wouldn't they release these numbers?